← Leaderboards
Mark Yondola
Avatar Medical, Llc
$8,546,778
Attributed
$8,695,187
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2015–22$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,695,187 · 6
By mechanism
R44$7,573,722 · 3
R43$1,121,465 · 3
Top collaborators
- Jason Scott Mclellan1 shared
Most similar at Avatar Medical, Llc
Same institution · by research overlap
- Christopher Marshall$1,496,475
- Evgeny Vulfson$298,591
- Jason Scott McLellan$14,153,484
- Roberto Mariani$149,426
Others in their field
Top investigators on “Antibody Formation”
- Dennis R. Burton · Scripps Research Institute$79,778,440
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Kent J. Weinhold · Duke University$41,978,341
- Rama Rao Amara · Emory University$34,508,664
- Rafi Ahmed · Emory University$28,122,278
- Barton F Haynes · Duke University$27,983,877
Research focus
Antibody FormationVirusAntigensImmune ResponseInnovationBaseMolecular ConformationCrosslinkResponseVaccinatedLeadBindingProteinsVaccinesImmunizeRecombinantsChimeric ProteinsRespiratory Syncytial Virus VaccinesCessation Of LifeElderlyHospitalizationCotton RatsAnimal ModelRespiratory Syncytial Virus
Grant awards (15)
An RSV Prefusion F Vaccine that Overcomes Immunosenescence$984,686
R44 · FY2022 · AG · contact PI
An RSV Prefusion F Vaccine that Overcomes Immunosenescence$989,026
R44 · FY2021 · AG · contact PI
An RSV Prefusion F Vaccine that Overcomes Immunosenescence$939,591
R44 · FY2020 · AG · contact PI
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA$887,615
R44 · FY2020 · AG · contact PI
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA$612,265
R44 · FY2019 · AG · contact PI
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA$374,928
R44 · FY2019 · AG · contact PI
An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination$299,955
R43 · FY2019 · AI · contact PI
An RSV Prefusion F Vaccine that Overcomes Immunosenescence$299,740
R44 · FY2019 · AG · contact PI
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA$986,704
R44 · FY2018 · AG · contact PI
An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination$299,787
R43 · FY2018 · AI · contact PI
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine$650,899
R44 · FY2017 · AI · contact PI
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine$98,819
R44 · FY2017 · AI · contact PI
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine$749,449
R44 · FY2016 · AI · contact PI
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine$296,818
R43 · FY2015 · AI · contact PI
A Universal Flu Vaccine Based on Conformationally Locked Soluble Headless HA$224,905
R43 · FY2015 · AI · contact PI